Last reviewed · How we verify
NCT05004337: VANISH
Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies
trial in Vanishing Twin in 126 participants. Completed in 29 November 2023.
29 November 2023
Quick facts
| Lead sponsor | Natera, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 126 |
| Start date | 22 July 2021 |
| Primary completion | 29 November 2023 |
| Estimated completion | 29 November 2023 |
| Sites | 21 locations across United States |
Conditions studied
- Vanishing Twin — all drugs for Vanishing Twin →
- Trisomy 21 — all drugs for Trisomy 21 →
- Trisomy 13 — all drugs for Trisomy 13 →
- Trisomy 18 — all drugs for Trisomy 18 →
Sponsor
Natera, Inc.
Who can join
18 and older, female only, with Vanishing Twin or Trisomy 21. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to collect blood samples from women carrying a vanishing twin pregnancy to further develop Natera's non-invasive prenatal screening test to provide information about possible chromosomal conditions for the living twin
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05004337
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Natera, Inc. trials
Trials by the same sponsor.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07046585 — Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC) · recruiting
- NCT06620627 — Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection · recruiting
- NCT05309382 — Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation · completed
- NCT05205551 — Prospera Test Evaluation in Cardiac Transplant (ProTECT) · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05004337 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Natera, Inc.
- Last refreshed: 25 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05004337.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing